Abstract
Warfarin is still the commonest drug used for clotting disorders but its use is complicated owing to wide interindividual variability in dose requirement and its narrow therapeutic index. New anticoagulants are very promising class of drugs, which are gradually replacing warfarin therapy.
So far, this treatment is limited to certain groups of specialists. Currently, dabigatran, rivaroxaban and apixaban is indicated in patients with atrial fibrillation, pulmonary embolis or deep vein thrombosis.
In the prevention of thromboembolism after orthopedic surgery, a reduced dose of rivaroxaban and dabigatran is used. In clinical praxis we must pay attention to kidney and liver function, as well as restrictions set by insurance companies.